Shipla Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.
Original Article: Early Pembrolizumab/Bevacizumab Study Shows Promise in RCC